entered into by LHNCBC pursuant to the Federal Technology Transfer Act of 1986, as amended by the National Technology Transfer Act (Pub. L. 104–113 (1996)) and by Executive Order 12591 of April 10, 1987. The Computer Science Branch, LHNCBC, NLM is presently developing a system to automate key decisions in the design and execution of machine learning applications. The system, termed ''cultural coevolution'' (COEV), uses object oriented intelligent agent techniques to synergistically integrate many different machine learning approaches into a single framework. The described methods are the subject of a provisional patent application (60/018,191) filed by the Government.

Under the present proposal, the goal of the CRADA will be the development of the following parameters:

- Improved speed of the algorithm;
- Improved portability of the system;
- Integration of ''data warehousing'' functions to enable compatibility with a wide variety of database formats, remedy gaps or errors in the data (''data cleaning'') and to identify target concepts for learning;
- Development of a user interface to enable system set up and configuration, monitor algorithm progression, adjust the algorithm as necessary, and display the results in a comprehensive and useful format.

Party Contributions

The role of the LHNCBC includes the following:

(1) Provide Collaborator with COEV system information necessary for the further development of the COEV system;

(2) Provide staff, expertise, and materials for the further development of the COEV system;

(3) Evaluate the work product of Collaborator to ensure progress toward meeting the CRADA goals; and

(4) Provide work space and equipment for production and testing of any components or improvements of the COEV system.

The role of the successful Collaborator will include the following:

(1) Provide funding, if and as necessary, in support of the development of the COEV system;

(2) Provide expertise and assistance in the production and marketing of any products resulting from this CRADA;

(3) Provide staff, expertise, and materials for the development of the COEV system under this CRADA; and

(4) Provide quality assurance testing, operator training, and user support for any products resulting from this CRADA.

Selection Criteria

Proposals submitted for consideration should fully address each of the following qualifications:

(1) Expertise

A. Demonstrated expertise in translating sophisticated statistical or machine learning methods to successful products;

B. Demonstrated expertise in software engineering, data warehousing, data visualization;

C. Demonstrated ability to secure national and international marketing and distribution of software;

D. Demonstrated expertise in overseeing all aspects of product development;

E. Demonstrated intellectual ability to guide development of product line which addresses the requirement of LHNCBC;

F. Demonstrated expertise in serving and supporting a significant client base; and

G. Familiarity with application of data mining techniques to biomedical fields.

(2) Reputation

The successful Collaborator must be recognized in the software industry for:

A. Producing, marketing and supporting data mining and related applications;

B. Indications of high levels of satisfaction by software experts and users of data mining products and;

C. The range of products and services it produces.

(3) Physical Resources

A. An established headquarters with offices, space, and equipment;

B. Access to the organization during business hours by telephone, mail, e-mail, the Internet, and other evolving technologies; and

C. Sufficient financial and technological resources to support, at a minimum, the current activities of the CRADA to meet the needs of LHNCBC.

Dated: April 1, 1997.

Thomas D. Mays,

Director, Office of Technology Development, National Cancer Institute, National Institutes of Health.

[FR Doc. 97–9238 Filed 4–9–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Opportunity for a Clinical Trial-Cooperative Research and Development Agreement (CT–CRADA) for Phase II Clinical Trial on the Use of Minocycline to Treat Osteoporosis

AGENCY: National Institutes of Health, PHS, DHHS.

ACTION: Notice.

SUMMARY: The National Institute of Aging (NIA) is seeking a Collaborator to participate in a CT–CRADA to run a Phase II clinical trial on the use of minocycline to treat osteoporosis, and to assist in the development of analogues to minocycline.

The term of the CT–CRADA will be up to five (5) years.

DATES: Interested parties should notify this office in writing of their intent to file a formal proposal no later than June 9, 1997. Formal proposals must be submitted to this office no later than July 9, 1997.

ADDRESSES: Inquiries and proposals regarding this opportunity should be addressed to Bruce D. Goldstein, J.D.; Office of Technology Development, National Cancer Institute; Executive Plaza South, Suite 450; 6120 Executive Blvd., MSC 7182, Bethesda, Maryland, 20892 (Telephone No. 301–496–0477; FAX No. 301–402–2117).

SUPPLEMENTARY INFORMATION: A CRADA is the anticipated joint agreement to be entered into by NIA pursuant to the Federal Technology Transfer Act of 1986, as amended by the National Technology Transfer Act (Pub. L. 104–113 (Mar. 7, 1996)) and by Executive Order 12591 of April 10, 1987. NIA has recently published a discovery by its staff that minocycline, an antibiotic related to tetracycline, increases bone mineral density, improves bone strength and formation, and slows bone resorption in old laboratory animals with surgically-induced menopause. Bone, 19:637–644 (Dec. 1996). Accordingly, NIA has begun to organize Phase II clinical trials.

Under the present proposal, the specific goals of the CT–CRADA will be the development of the following technology:

- Development of one or more protocols for the clinical trial of minocycline in the treatment of osteoporosis;
- Execution of clinical trials;
- Joint publication of research results; and

• Development of improved derivatives of minocycline.

Party Contributions

The role of NIA includes the following:

(1) Develop and file, in consultation with Collaborator, any and all regulatory applications for the use of minocycline in the treatment of osteoporosis;

(2) Provide staff, expertise, and materials for the development and execution of protocols, and for the development and testing of promising minocycline analogues;

(3) Together with the Collaborator, evaluate the results of joint research, and to ensure progress toward meeting the CT–CRADA goals; and

(4) Provide work space and equipment for testing of any prototype pharmaceutical compositions developed.

The role of the successful Collaborator will include the following:

(1) Provide staff, expertise, and materials for the development and production of pharmaceutical compositions;

(2) Purchase or manufacture an adequate supply of minocycline;

(3) Together with NIA, evaluate the results of joint research, and to ensure progress toward meeting the CT–CRADA goals;

(4) Provide funding in support of the clinical trials; and

(5) Provide resource to develop and market any promising analogues to minocycline.

Selection Criteria

Proposals submitted for consideration should fully address each of the following qualifications:

(1) Expertise

The successful Collaborator should have the following expertise:

A. Demonstrated expertise in developing and producing high quality pharmaceutical compositions;

B. Demonstrated ability to secure national and/or international marketing and distribution of pharmaceutical compositions;

C. Demonstrated expertise in overseeing all aspects of product development;

D. Demonstrated intellectual ability to guide development of product line which addresses the requirements of NIA.

(2) Reputation

The successful Collaborator should be recognized in the pharmaceutical industry for each of the following:

A. Producing quality pharmaceutical products;

B. Indications of high levels of satisfaction by industry experts with the Collaborator's products; and

C. Strong commitment to the research and development of new pharmaceuticals.

(3) Physical Resources

The successful Collaborator should be able to demonstrate it will have the following material resources as of the commencement of research under the CT–CRADA:

A. An established headquarters with offices, space, and equipment;

B. Adequate means for communication with the Collaborator during business hours, such as by telephone, mail, e-mail, the Internet, and other evolving technologies; and

C. Sufficient financial resources to support, at a minimum, the current activities of the CT–CRADA to meet the needs of NIA.

Dated: March 26, 1997.

Thomas D. Mays,

Director, Office Technology Development, National Cancer Institute, NIH.

[FR Doc. 97–9239 Filed 4–9–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Child Health and Human Development Special Emphasis Panel (SEP) meeting:

Name of SEP: Specialized Clinical Fellowships (Teleconference).

Date: May 5, 1997.

Time: 1:00 p.m.—adjournment.

Place: 6100 Executive Boulevard, 6100 Building Room 5E03, Rockville, Maryland 20852.

Contact Person: Hameed Khan, Ph.D., Scientific Review Administrator, NICHD, 6100 Executive Boulevard, 6100 Building, Room 5E01, Rockville, Maryland 20852, Telephone: 301–496–1485.

Purpose/Agenda: To evaluate and review grant applications.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The discussions of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. [93.864, Population Research and No. 93.865, Research for Mothers and Children, National Institutes of Health].)

Dated: April 7, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–9297 Filed 4–9–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke, Division of Extramural Activities; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel (Telephone Conference Call).

Date: April 23, 1997.

Time: 9:00 a.m.

Place: National Institutes of Health, 7550 Wisconsin Avenue, Room 9C10, Bethesda, MD 20892.

Contact Person: Dr. Howard Weinstein/Mr. Phillip Wiethorn, Scientific Review Administrator, National Institutes of Health, 7550 Wisconsin Avenue, Room 9C10, Bethesda, MD 20892, (301) 496–9223.

Purpose/Agenda: To review and evaluate an SBIR Phase II Contract Proposal.

The meeting will be closed in accordance with the positions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program No. 93.853, Clinical Research Related to Neurological Disorders; No. 93.854, Biological Basis Research in the Neurosciences).

Dated: April 7, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–9298 Filed 4–9–97; 8:45 am]

BILLING CODE 4140–01–M